首页> 外文期刊>Cardiovascular Research >Arrhythmogenic cardiomyopathy: pathogenesis, pro-arrhythmic remodelling, and novel approaches for risk stratification and therapy
【24h】

Arrhythmogenic cardiomyopathy: pathogenesis, pro-arrhythmic remodelling, and novel approaches for risk stratification and therapy

机译:心律病药心肌病:发病机制,临时改造和风险分层和治疗的新方法

获取原文
获取原文并翻译 | 示例
           

摘要

Arrhythmogenic cardiomyopathy (ACM) is a life-threatening cardiac disease caused by mutations in genes predominantly encoding for desmosomal proteins that lead to alterations in the molecular composition of the intercalated disc. ACM is characterized by progressive replacement of cardiomyocytes by fibrofatty tissue, ventricular dilatation, cardiac dysfunction, and heart failure but mostly dominated by the occurrence of life-threatening arrhythmias and sudden cardiac death (SCD). As SCD appears mostly in apparently healthy young individuals, there is a demand for better risk stratification of suspected ACM mutation carriers. Moreover, disease severity, progression, and outcome are highly variable in patients with ACM. In this review, we discuss the aetiology of ACM with a focus on proarrhythmic disease mechanisms in the early concealed phase of the disease. We summarize potential new biomarkers which might be useful for risk stratification and prediction of disease course. Finally, we explore novel therapeutic strategies to prevent arrhythmias and SCD in the early stages of ACM.
机译:致心律失常性心肌病(ACM)是一种危及生命的心脏病,由主要编码桥粒蛋白的基因突变引起,这种突变导致闰盘分子组成的改变。ACM的特征是心肌细胞逐渐被纤维脂肪组织替代、心室扩张、心功能不全和心力衰竭,但主要是发生危及生命的心律失常和心源性猝死(SCD)。由于SCD主要出现在表面健康的年轻人身上,因此需要对疑似ACM突变携带者进行更好的风险分层。此外,ACM患者的疾病严重程度、进展和预后高度可变。在这篇综述中,我们讨论了ACM的病因,重点是该疾病早期隐匿期的促心律失常疾病机制。我们总结了可能有助于风险分层和疾病进程预测的潜在新生物标志物。最后,我们探索了新的治疗策略,以预防ACM早期心律失常和SCD。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号